$9.34
0.69% today
Nasdaq, Feb 28, 08:48 pm CET
ISIN
US77313F1066
Symbol
RCKT
Sector
Industry

Rocket Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation

Rocket Pharmaceuticals, Inc. Classifications & Recommendation:

Buy
94%
Hold
6%

Rocket Pharmaceuticals, Inc. Price Target

Target Price $43.93
Price $9.40
Potential
Number of Estimates 14
14 Analysts have issued a price target Rocket Pharmaceuticals, Inc. 2026 . The average Rocket Pharmaceuticals, Inc. target price is $43.93. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 16 analysts: 15 Analysts recommend Rocket Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Rocket Pharmaceuticals, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Rocket Pharmaceuticals, Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -2.92 -2.77
10.43% 5.14%
P/E negative
EV/Sales 33,322.67

5 Analysts have issued a Rocket Pharmaceuticals, Inc. forecast for earnings per share. The average Rocket Pharmaceuticals, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-2.77
Unlock
. This is
0.73% lower
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-2.45 10.91%
Unlock
, the lowest is
$-2.95 7.27%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-2.92 10.43%
2024
$-2.77 5.14%
Unlock
2025
$-2.16 22.02%
Unlock
2026
$-1.10 49.07%
Unlock
2027
$0.35 131.82%
Unlock
2028
$9.40 2,585.71%
Unlock
2029
$10.55 12.23%
Unlock

P/E ratio

Current -3.41 62.57%
2024
-3.44 0.88%
Unlock
2025
-4.34 26.16%
Unlock
2026
-8.54 96.77%
Unlock
2027
26.86 414.52%
Unlock
2028
1.00 96.28%
Unlock
2029
0.89 11.00%
Unlock

Current Rocket Pharmaceuticals, Inc. Upgrades & Downgrades Beta

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Jefferies Locked ➜ Locked Locked Dec 18 2024
Needham Locked ➜ Locked Locked Nov 19 2024
Canaccord Genuity Locked ➜ Locked Locked Nov 19 2024
Cantor Fitzgerald Locked ➜ Locked Locked Nov 19 2024
Leerink Partners Locked ➜ Locked Locked Nov 19 2024
Chardan Capital Locked ➜ Locked Locked Nov 18 2024
Chardan Capital Locked ➜ Locked Locked Nov 11 2024
Analyst Rating Date
Locked
Jefferies: Locked ➜ Locked
Dec 18 2024
Locked
Needham: Locked ➜ Locked
Nov 19 2024
Locked
Canaccord Genuity: Locked ➜ Locked
Nov 19 2024
Locked
Cantor Fitzgerald: Locked ➜ Locked
Nov 19 2024
Locked
Leerink Partners: Locked ➜ Locked
Nov 19 2024
Locked
Chardan Capital: Locked ➜ Locked
Nov 18 2024
Locked
Chardan Capital: Locked ➜ Locked
Nov 11 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today